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Migraine pathophysiology remains
elusive. A relationship between
migraine and epilepsy has been pro-
posed [1] and antiepileptic drugs
(AEDs) are being used extensively
for migraine prophylaxis and treat-
ment. Newer AEDs with novel mech-
anisms of action may also help to pre-
vent and treat migraines. The avail-
ability of an IV form of an AED
allows rapid administration and there-
fore could be used in the management
of status migrainosus (SM). Leveti-
racetam (LEV) is one of the newer
AEDs and has multiple mechanisms
of action including favourable inter-
actions with gamma amino butyric
acid (GABA) and glycine receptors,
antagonism of the activity of negative
modulators of GABA, modulation of
N-type calcium and glycine-gated
currents, and the selective binding to
the synaptic vesicle protein 2A [2, 3].
The role of LEV in prophylaxis of
refractory migraines and other
headache syndromes has been report-
ed [4–7]. The IV form of levetirac-
etam (IV-LEV) has recently become
available. With all the advantages of
the newer-generation AEDs, includ-
ing the minimal side effects and drug
interactions, IV-LEV might also be a
potential candidate for the treatment
of migraine and SM.
We report the case of a 27-year-
old woman with a history of migraine
with aura and complex partial (CP)
epilepsy with occasional secondary
generalisation. She had been seizure-
free on oral LEV 750 mg twice daily
for 2 years. She came to the emer-
gency department (ED) with worsen-
ing of her usual migraine headaches
for more than 72 h. In the ED, she
suffered a 2-min episode of CP
seizure with secondary generalisation
and was given an infusion of 1000 mg
IV-LEV over 15 min. She returned to
her clinical baseline and her headache
resolved 35 min after the infusion.
She tolerated the infusion well and
without side effects. She was
observed for 24 h and maintained on
her usual oral LEV without any
breakthrough seizures or headaches.
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